Skip to content
Plasma-Safe-SeqS
AML-SEQ™

Detection of the most clinically relevant mutations in AML

AML-SEQ™ demonstrates ultra-sensitive detection of the most common Acute Myeloid Leukemia (AML) biomarkers with maximum efficiency to improve outcomes for one of the deadliest blood cancers by monitoring therapy efficacy and analyzing risk of relapse.

Panel features

CLIA-validated, ultra-sensitive blood test for the detection of IDH1, IDH2, and NPM1, this panel detects as few as 10 mutant molecules in a background of 20,000 wild-type molecules (0.05% mutant allele frequency).

View our other
Oncology Panels

View
ico
HPV-SEQ

Quantify HPV 16/18 from blood

  • HPV 16

  • HPV 18

Learn more
ico
HNSCC-SEQ

HPV(-) HNSCC mutation detection

  • CDKN2A

  • EGFR

  • ERBB2

  • FGFR3

  • HRAS

  • KRAS

  • NOTCH1

  • PIK3CA

  • PTEN

  • TP53

Learn more
ico
AML-SEQ™

Detect prevalent mutations with confidence

  • IDH1

  • IDH2

  • NPM1

Learn more
ico
AML-MRD-SEQ

A panel of promise for AML-MRD

  • FLT3

  • IDH1

  • IDH2

  • NPM1

  • BCOR

  • BRAF

  • CEBPA

  • GATA2

  • JAK2

  • KIT

  • KRAS

  • NRAS

  • PRPF8

  • PTPN11

  • SETBP1

  • SF3B1

  • SRSF2

  • TP53

  • U2AF1

  • ZRSR2

Learn more
ico
RAS-RAF-SEQ

RAS-RAF & PIK3 pathway markers

  • BRAF

  • KRAS

  • NRAS

  • AKT1

  • PIK3CA

Learn more
ico
BC-SEQ

Breast Cancer mutation detection

  • AKT1

  • ERBB2

  • ESR1

  • KRAS

  • PIK3CA

  • TP53

Learn more
Contact

We’d love to hear from you!

Hidden
Hidden
Hidden
Hidden
Hidden
Hidden